Cellular responses to retroviral capsid recognition
Cellular responses to retroviral capsid recognition
批准号:
10626905
负责人:
Michael Aaron Mandell
金额:
$41.48万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-06-17 至 2026-05-31
关键词:
AddressAllelesAnti-Inflammatory AgentsAnti-Retroviral AgentsAntiviral ResponseAntiviral TherapyAutophagocytosisAutophagosomeBindingBiochemicalBiogenesisBiologicalCapsidCell SurvivalCellsComplexCytoplasmCytoprotectionDNADataDegradation PathwayDetectionDevelopmentDiseaseEvolutionFamilyFlavivirusFoundationsGenesGeneticGoalsHIVHIV InfectionsHIV-1HomeostasisHost DefenseHumanImmuneImmune signalingImmunologicsIndividualInfectionInflammationInflammatoryInterferon alphaInterferonsKnowledgeLife Cycle StagesLigationLinkMalignant NeoplasmsMediatingMembraneMethodologyModelingMolecularNatural ImmunityOutcomePathogenicityPathway interactionsPattern RecognitionPattern recognition receptorPersonsPhosphotransferasesPlayPositioning AttributePredispositionPrimate RetrovirusProcessProductionProtein FamilyProtein IsoformsProteinsProteomicsPublishingQuality ControlRegulationReportingRetroviridaeRiskRoleSchizophreniaShapesSignal PathwaySignal TransductionSignaling ProteinSystemTBK1 geneTRIM FamilyTRIM5 geneTestingTherapeuticViralViral PhysiologyViral ProteinsVirusVirus DiseasesWorkcytokinehuman diseaseimmune activationinnovationinsightnovelresponsescaffoldtransmission process
中文摘要
项目摘要:TRIM5是一种多功能抗病毒蛋白,其在宿主防御中的多种作用
英文摘要
PROJECT SUMMARY: TRIM5 is a multi-functional antiviral protein whose various actions in host defense are
still being uncovered. Understanding the molecular mechanisms underlying these antiviral actions is an
essential step towards the possible development of TRIM5-based host-directed antiviral therapies. TRIM5 is
best known as an antiviral effector against diverse families of viruses including flaviviruses and retroviruses.
TRIM5 also has roles in antiviral signaling that can trigger the expression of cytokines including type 1
interferon in response to retroviral pattern recognition. We previously reported a third major role for TRIM5: it
acts as a positive regulator of autophagosome biogenesis and it physically interacts with proteins acting in
multiple steps of the autophagy pathway. This raises the question of what the autophagy pathway and/or the
autophagy machinery might be contributing to TRIM5’s antiviral activities. In this project, we will answer this
question and work towards the long-term goal of understanding how TRIM5 coordinates its actions in
defending against retroviral infection. Our preliminary data demonstrate that cells lacking autophagy-related
proteins (ATGs) involved in upstream autophagy regulation, autophagosome membrane elongation, and
autophagic cargo selection are unable to carry out TRIM5-directed inflammatory signaling. Whereas autophagy
is typically considered a degradative process, in this setting the ATGs tested contributed to assembling active
TRIM5 signaling complexes. This suggests that TRIM5 orchestrates novel, non-canonical functions of the
ATGs with which it interacts. These findings support a hypothesis in which TRIM5’s actions in inflammatory
signaling and in establishing an antiviral state are linked to its actions in autophagy. We will use cell biological,
immunological, and proteomic approaches to test this hypothesis. We will uncover the role(s) of the autophagy
pathway and individual autophagy-related proteins in TRIM5-dependent antiviral signaling (Aims 1 and 2). Our
third Aim will uncover a novel TRIM5 signaling pathway connected to the inflammatory and autophagy-
regulatory kinase TBK1, which we identified as a retrovirus-responsive TRIM5 interactor through proteomic
analysis. Understanding TRIM5 signaling is significant, since TRIM5 signaling could explain why certain TRIM5
alleles confer protection against HIV infection in people despite human TRIM5’s relative inability to directly
restrict HIV. As outcomes, we anticipate that our proposed studies will: i) reveal novel pathways for antiviral
defense; ii) enable our understanding of how cells respond to detection of retroviral infection; and iii) provide
mechanistic insight into how TRIM5, a protein that has shaped the evolution of primate retroviruses, acts in
antiviral defense and innate immunity. We also expect that our findings will shed light on the broader TRIM
family of proteins (TRIMs). This protein family consists of roughly 80 genes in humans. Like TRIM5, many
TRIMs also have roles in antiviral defense, inflammation, and autophagy; thus understanding TRIM5 may
provide a firm foundation for the study of other TRIMs.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.pntd.0010893
发表时间:
2022-10
期刊:
PLoS neglected tropical diseases
影响因子:
3.8
作者:
[]
通讯作者:
The retroviral restriction factor TRIM5/TRIM5α regulates mitochondrial quality control.
逆转录病毒限制因子 TRIM5/TRIM5α 调节线粒体质量控制。
DOI:
10.1080/15548627.2022.2084863
发表时间:
2023
期刊:
Autophagy
影响因子:
13.3
作者:
[Saha,Bhaskar, Mandell,MichaelA]
通讯作者:
Mandell,MichaelA
Interactomic analysis reveals a homeostatic role for the HIV restriction factor TRIM5α in mitophagy.
DOI:
10.1016/j.celrep.2022.110797
发表时间:
2022-05-10
期刊:
CELL REPORTS
影响因子:
8.8
作者:
[Saha, Bhaskar, Salemi, Michelle, Williams, Geneva L., Oh, Seeun, Paffett, Michael L., Phinney, Brett, Mandell, Michael A.]
通讯作者:
Mandell, Michael A.
Cellular responses to retroviral capsid recognition
-
批准号:10296179
-
项目类别:
-
资助金额:$41.48万
-
财政年份:2021
-
负责人:Michael Aaron Mandell
-
依托单位:
Cellular responses to retroviral capsid recognition
-
批准号:10436986
-
项目类别:
-
资助金额:$41.48万
-
财政年份:2021
-
负责人:Michael Aaron Mandell
-
依托单位:
Prevention of HIV-induced T cell killing by autophagy
-
批准号:9761444
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2018
-
负责人:Michael Aaron Mandell
-
依托单位:
TRIM-directed autophagy in HIV restriction and control of inflammation
-
批准号:10249120
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2017
-
负责人:Michael Aaron Mandell
-
依托单位:
TRIM-directed autophagy in HIV restriction and control of inflammation
-
批准号:9207191
-
项目类别:
-
资助金额:$30.71万
-
财政年份:--
-
负责人:Michael Aaron Mandell
-
依托单位:
海外基金